key: cord-0698033-cul0t13h
authors: Dave, Tarjani Vivek; Gopinathan Nair, Akshay; Hegde, Raghuraj; Vithalani, Nidhi; Desai, Savari; Adulkar, Namrata; Kamal, Saurabh; Mittal, Raman; Bradoo, Renuka A.
title: Clinical Presentations, Management and Outcomes of Rhino-Orbital-Cerebral Mucormycosis (ROCM) Following COVID-19: A Multi-Centric Study
date: 2021-07-27
journal: Ophthalmic Plast Reconstr Surg
DOI: 10.1097/iop.0000000000002030
sha: 5c5a93170dff9419a4850f79afe0bd7a8e9011c2
doc_id: 698033
cord_uid: cul0t13h

To report clinical presentations and factors affecting outcomes in rhino-orbital-cerebral mucormycosis following COVID-19. METHODS: Retrospective multi-centric interventional case series of 58 eyes with rhino-orbital-cerebral mucormycosis. Demography, clinical parameters and management outcomes were noted. Factors affecting outcome and mortality were analyzed. Outcome was defined as favorable when complete resolution or stabilization without further progression of the infection was noted at last visit. RESULTS: Mean age was 55 ± 11 years (median 56). The mean HbA1c value was 10.44 ± 2.84 mg% (median 10.5). The duration between the diagnosis of COVID-19 and rhino-orbital-cerebral mucormycosis was 16 ± 21 days (median: 8 days). Thirty-six eyes (62%) had no vision at presentation. Imaging revealed paranasal sinus involvement (100%), orbital apex involvement (41%), cavernous sinus involvement (30%), and central nervous system (CNS) involvement (33%). All the patients were treated with systemic Liposomal amphotericin-B and sinus debridement. Twenty-two eyes (38%) underwent exenteration. One eye underwent transcutaneous retrobulbar amphotericin-B. The mean follow-up duration was 5.62 ± 0.78 months (median 6). Favorable outcome was seen in 35 (60%) cases. Presence of uncontrolled diabetes (p = 0.001), orbital apex involvement (p = 0.04), CNS involvement (p = 0.04), and history of steroid use (p < 0.0001) resulted in unfavorable outcome. CNS involvement was the only factor predicting mortality (p = 0.03). Mortality was seen in 20 (34%) patients. CONCLUSION: Over a third of patients with rhino-orbital-cerebral mucormycosis following COVID-19 have an unfavorable clinical outcome. Uncontrolled diabetes mellitus at presentation, involvement of the orbital apex, CNS, and the usage of steroids were associated with poorer outcomes. CNS involvement was a factor determining mortality.

i. Concurrently or recently (<6 weeks) treated for COVID- 19; ii. Uncontrolled diabetes mellitus (DM) (HbA1c of >7% was considered as the cutoff value for diagnosing uncontrolled diabetes); iii. Treated for COVID-19 with steroids; iv. Treated for COVID-19 with immunomodulators (tocilizumab).

i. Diagnostic nasal endoscopy: Signs of nasal eschar, discoloration, and ulceration over the nasal mucosa were examined in the region of the middle turbinate, middle meatus, and the septum.

ii. MRI orbit, paranasal sinus and brain with gadolinium contrast was performed and fat saturation postcontrast sequences were examined. i. Mycological evidence of mucormycosis in tissue biopsy taken during sinus debridement or from the orbital biopsy. Direct examination of biopsy or aspirated material was performed using 10% potassium hydroxide or calcofluor white staining solution. The specimens were inoculated on Sabouraud dextrose agar and blood agar and incubated at 37°C and 25°C for up to 1 and 2 weeks, respectively. Rapid growth of gray fluffy colonies was identified on conventional morphologic assessment. The growth was sub-cultured and reported as significant if the direct examination of the sample showed the presence of fungal filaments. 15 ii. Histopathologic evidence of mucormycosis in tissue biopsy was performed by examining for aseptate hyphae branching at wide-angle and ribbon-like  hyphae associated with tissue damage on slides stained  by Hematoxylin and Eosin, Periodic acid Schiff, and Gomori's methenamine silver stains.

Along with indicative clinical signs and symptoms, mucormycosis was classified as possible if any of the host factors were present, probable if host factors and any of the diagnostic factors were present, and proven if host factors and diagnostic factors were present with mycological criteria being met.

The diagnosis of COVID-19 was based on real-time polymerase chain reaction test on nasopharyngeal/oropharyngeal swabs. All demographic and clinical characteristics including ophthalmic signs, systemic manifestations, underlying conditions, and medical and surgical interventions were noted. The data recorded included age, gender, duration of the symptoms, history of DM, status of control of DM at presentation, any other immune deficiencies, clinical/radiologic involvement of the orbital apex, cavernous sinus, or the central nervous system (CNS), history of steroid use and that of immunomodulators (tocilizumab), the CT severity scores and the CORAD scores. The presence of thrombo-embolic phenomenon related to COVID-19 was evaluated by the treating internist. A favorable outcome was defined as a complete resolution of the infection or stabilization without further progression on radiology at the end of follow-up.

Statistical Analysis. The data was arranged on an Excel spreadsheet. Relevant statistical analysis was done using MedCalc version 12.2.1.0 (Ostend, Belgium). Continuous parametric data were reported using the mean (±SD) and nonparametric data were reported as median. Multivariate logistic regression analysis and chi-square test were performed to assess the effect of multiple factors that might have influenced the outcome and mortality. A p-value of <0.05 was assigned as statistically significant. Outcomes of both the bivariate and multivariate analysis were reported for comparison.

The study included 58 eyes of 58 patients. All patients developed ROCM following COVID-19 infection. There were 44 males (76%). The mean age was 55 ± 11 (median 56) years. Forty-three patients (74%) had a history of DM. On presentation with COVID-19 symptoms, 46 (79%) patients had uncontrolled diabetes based on the glycosylated hemoglobin values (HbA1c). An HbA1c of 7% or higher was considered as the cutoff value for diagnosing uncontrolled DM. The mean HbA1c value among those with controlled DM was 5.84 ± 0.54 mg% (median: 6), while that in uncontrolled cases was 11.57 ± 1.86 mg% (median 11.25) (p < 0.0001). The mean chest CT severity score was 15.95 ± 4.74 (median: 17) . No thrombo-embolic phenomenon attributable to COVID-19 was noted in any of the patients in this subset. The duration between the diagnosis of COVID-19 and ROCM was 16 ± 21 days (median: 8 days). Thirty-six eyes (62%) had no perception of light at presentation. A further 9 patients (16%) patients had perception of light only, 7 patients (12%) had to count fingers close to face at presentation and the rest had ambulatory vision or more. Three patients had a presenting visual acuity of 20/20.

Orbital pain and headache were noted in 78% and 59% of cases, respectively. Seventy-two percent of patients had proptosis while ptosis was noted in 69%. Extraocular muscle limitation was noted in 93% of cases. Of interest, mouth lesions were seen in 14% and the classic black eschar was noted in 33% of cases. On imaging, features of orbital cellulitis and orbital abscess were seen in 74%. Other imaging features included paranasal sinus involvement (100%), orbital apex involvement (41%), CNS involvement (33%), and cavernous sinus involvement (30%). The mean C-reactive protein was elevated to 47.19 ± 53.43 mg/L (median 26.9) ( Table 2) .

Sinus debridement and systemic treatment with antifungals were performed in all patients. Induction treatment was initiated with intravenous liposomal amphotericin-B in a dose of 5 mg/kg/day under monitoring by an infectious disease specialist for renal paraments for 2 weeks. Following this, maintenance therapy was with oral posaconazole in a dose of 300 mg BD for day 1 followed by 300 mg OD for a period of 4-6 weeks. Eight (14%) patients, were unable to complete the 2 weeks induction therapy with liposomal amphotericin-B in view of systemic complications and were shifted to maintenance therapy early. The antifungals were stopped after no progression on clinical examination or on radiology was noted. A small subset of 3 patients had panophthalmitis with localized orbital abscess in the anterior orbit. These patients underwent evisceration along with orbital debridement of the necrotic tissue until fresh bleeding was noted. Following debridement, the orbital cavity was irrigated with 5 ml of amphotericin-B in a dose of 1 mg/ml. One of these 3 patients progressed on treatment and required exenteration (Fig. 2 ). One patient who had localized orbital apex involvement with contrast uptake was treated with transcutaneous retrobulbar amphotericin-B in a dose of 3.5 mg/ml for 5 consecutive days. External ophthalmoplegia reversed in this patient and she was radiologically stable at the end of follow-up >6 months (Fig. 3) . The radiologic involvement, clinical presentation, and tissue diagnosis from the sinus debridement were used as a guide to decide on exenteration versus globe salvage. Patients with proven mucormycosis, extensive orbital involvement producing globe tenting, those with diffuse loss of contrast enhancement in the orbit and those with apical involvement were considered for exenteration. Exenteration was also performed when there was documented progression of disease despite maximal medical therapy and surgical debridement. Twenty-two eyes (38%) underwent exenteration with debridement of the necrotic sinonasal tissue (Fig. 4) . The mean follow-up duration was 5.62 ± 0.78 months (median 6). A favorable final outcome with respect to management of ROCM was seen in 35 (60%) cases. An unfavorable outcome was seen in 23 patients (40%). Of these mortality was seen in 20 (34%) and in the remaining 3 (6%) patients the disease remained unchanged on radiology at the end of follow-up.

Various demographic and clinical factors were assessed by bivariate and multivariate regression analysis to predict those that determined an unfavorable outcome (Table 3) . Age, gender, duration of complaints, controlled DM, and usage of immunomodulator tocilizumab had no effect on the final outcome. Bivariate regression analysis showed a significant negative effect of cavernous sinus involvement on the final outcome but this effect was not statistically significant in multivariate analysis. Similarly, CT severity score (p = 0.03) and exenteration 

(p = 0.008) were associated with higher mortality on bivariate regression analysis. However, this significance was not maintained on multivariate regression analysis (p = 0.7 and 0.6, respectively). The presence of uncontrolled diabetes, orbital apex involvement, CNS involvement, and the usage of steroids were responsible for an unfavorable outcome. These factors were also assessed for their effect on mortality (Table 4) . Both bivariate and univariate analysis showed CNS involvement at presentation as the only factor predicting mortality (p = 0.002 and 0.03, respectively).

The current study is the largest multi-centric series of ROCM following COVID-19 with long-term outcomes. We noted 40% of all cases have an unfavorable outcome. Factors determining unfavorable outcome included uncontrolled DM at presentation, involvement of the orbital apex and CNS, and the usage of steroids during the active phase of COVID-19 infection. The mere presence of DM, or usage of immunomodulators did not pose a significant risk for an unfavorable outcome. Twenty-two patients (38%) required an orbital exenteration.

COVID-19 and mucormycosis share risk factors, such as presence of DM, which can independently contribute to mortality, but have conflicting management principles. While immune suppression with steroids may be required in moderate to severe COVID-19, the use of steroids and the worsening glycaemic control provide an opportunity for mucor to become invasive. 9, [16] [17] [18] [19] [20] [21] Mucor produces keto-reductase as a virulence factor enabling them to grow in the acidic and glucose-rich environment generated in ketoacidotic states. 9, [17] [18] [19] Additionally, Müller et al 22 29 reported a case of invasive fungal rhinosinusitis with orbital involvement in a patient with COVID-19 with uncontrolled DM and HbA1c of 14%. In the current study too, we found usage of steroids as a factor predicting unfavorable outcome. Mehta and Pandey 11 reported a case of a patient with COVID-19 infection, treated with steroids and tocilizumab, who during the course of the treatment, developed rhino-orbital mucormycosis. Due to persistent hypotension, repeat imaging or debridement measures were not possible and the patient died on day 6 of admission. Waizel-Haiat et al 12 reported a case of rhino-orbital mucormycosis associated with ketoacidosis secondary to recent onset DM and COVID-19 infection. Despite aggressive management the patient developed multi-organ failure and died. Similar to this particular patient, 27 (47%) patients in our series received tocilizumab, an immunomodulator (anti-interleukin 6 receptor antibody) that improves the outcome of COVID-19 infections. It is known that tocilizumab can precipitate invasive fungal infections. 30, 31 Though, in our study the usage of tocilizumab had a near significance (p = 0.07) in bivariate analysis, this was not maintained in the multivariate analysis (p = 0.89). This may suggest that usage of tocilizumab had some bearing on an unfavorable outcome but could not be proven statistically in our subset. 

Ophthalmic Plast Reconstr Surg, Vol. 37, No. 5, 2021 Moorthy et al 21 published a series of 31 patients with ROCM following COVID-19 and suggested that the presence of cerebral involvement and a HbA1c value of ≥8 were found to be significant in the prediction of mortality in this subset. Our findings are in accordance to this observation. A comparison of our study with published literature on COVID-associated mucormycosis is summarized in Table 5 .

The largest series on ROCM from a geographically similar area with patients who did not have COVID-19 was published by Nithyanandam et al. 33 They reported a retrospective series of 34 cases of ROCM treated more than 8 years (1992-2000) . The cases were treated with intravenous amphotericin-B and appropriate debridement and exenteration as per the clinical condition. Uncontrolled diabetes constituted 82% of their cases, as against 76% in the current series (p = 0.5). Intracranial disease in that series was seen in 7 of 34 cases (21%) while in the current series it was 33% (p = 0.2). The overall mortality in the series was seen in 11 patients (32%). This was comparable to the mortality rate in our study which was 34% (p = 0.87). The treatment success rates of their study and the current study were 53% and 60%, respectively (p = 0.49). The commonest parameters between the 2 studies were not statistically different. This indicates that the concurrent COVID-19 infection does not alter either the final outcome or the mortality in cases with mucormycosis. One of the most important decisions that needs to be made in the course of the management of ROCM is that regarding orbital exenteration. It has been previously reported that the indications for orbital exenteration are ophthalmoplegia, proptosis, cranial involvement, and ocular involvement. [32] [33] [34] [35] [36] [37] [38] [39] Some have even reported that exenteration could increase the patients' survival in the presence of intracranial spread and rapid progression. 34 Kashkouli et al 17 in their series found that survival was not significantly different in patients with and without exenteration. However, a significantly longer duration of symptom to death was observed in patients with exenteration indicating that performing orbital exenteration may delay the time of death. There have been attempts to create a scoring system to assist in the management of ROCM. Shah et al 40 proposed the "Sion Hospital Scoring System" which relies on clinical signs, ophthalmoscopic features, and imaging characteristics. However, it is also possible that exenteration, by itself, may not be associated with improved survival due to end-stage disease at the time of exenteration. 35 In our study, bivariate regression analysis showed exenteration to be associated with higher mortality (p = 0.008) although the significance was not maintained on multivariate analysis. This statistical observation could be confounded by the possibility that patients with the most severe infections and the highest risk of dying were exenterated. Another possibility might be that exenteration did not confer a survival benefit. We believe, in cases of ROCM involving the sinuses, the orbit along with intracranial extension, orbital exenteration at best may help in reducing the disease load; which by itself cannot be curative.

The current study has its strengths and limitations. This is the largest study to date on ROCM in COVID-19 patients and also the first one to objectively demonstrate the factors predicting poor clinical outcomes along with those predicting mortality in such a subset. The current study proposes various independent factors that determine clinical outcomes in ROCM following COVID-19 infection. As seen in the regression tables, the variance inflation factors of all the significant independent variables are on the lower side. This rules out multi-collinearity and we can thus propose each of these to be an independent significant factor not affected by the other. This is a major strength of this study. This study also has limitations of being a retrospective study across different practices separated by geography. Thus a slight difference in management protocols cannot be adjusted for.

In conclusion, ROCM is a known occurrence in COVID-19 affected patients. Over a third of patients can have unfavorable final outcome. Uncontrolled DM at presentation, involvement of the orbital apex and CNS by the infection, and the usage of steroids determined an unfavorable outcome. Involvement of the CNS was seen to be the only factor determining mortality. In a similar geographic setup, as compared to previous non-COVIDrelated cases, the coexistence of COVID-19 in this series, did not seem to worsen the final outcome in terms of mortality. It is prudent that physicians and ophthalmologists, alike, involved in the care of patients with COVID-19 be aware of the outcomes of ROCM in COVID-19 patients.

Rhino-orbitalcerebral mucormycosis

Ten years' experience in zygomycosis at a tertiary care centre in India

Novel perspectives on mucormycosis: pathophysiology, presentation, and management

Zygomycetes in human disease

International Diabetes Federation 2020

Diagnosis and management of rhino-orbitocerebral mucormycosis (phycomycosis). A report of 16 personally observed cases

World Health Organization. Coronavirus disease (COVID-19) pandemic

Bacterial and fungal infections in COVID-19 patients: a matter of concern

The microbial coinfection in COVID-19

COVID-19 and fungal infection: the need for a strategic approach

Rhino-orbital mucormycosis associated with COVID-19

A case of fatal Rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19

Mucor in a viral land: a tale of two pathogens

Code mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19

Detection of fungi by conventional methods and semi-nested PCR in patients with presumed fungal keratitis

Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China

Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis

Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro

In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus

Combination of lymphocyte number and function in evaluating host immunity

SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? a retrospective, multicentric analysis

SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas

COVID-19 and orbital mucormycosis

A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient

Rhinocerebral mucormycosis acquired after a short course of prednisone therapy

Mucormycosis of the head and neck: report of five cases with different presentations

Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: clinico-radiological features

Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum

Acute invasive Rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome

Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis

Late onset infectious complications and safety of tocilizumab in the management of COVID-19

Rise of the phoenix: mucormycosis in COVID-19 times

Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes

Rhinocerebral mucormycosis: evolution of the disease and treatment options

Rhinocerebral mucormycosis: experience in 14 patients

Rhinocerebral mucormycosis: consideration of prognostic factors and treatment modality

Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis

Improving outcomes in rhinocerebral mucormycosis-early diagnostic pointers and prognostic factors

Evaluation of 28 cases of mucormycosis

Orbital exenteration in rhinoorbito-cerebral mucormycosis: a prospective analytical study with scoring system